There have been a number of studies that have suggested that some common medications will alter prostate-specific antigen (PSA) levels. Researchers from Stanford University School of Medicine, Stanford, CA., investigated the impact of individual and combinations of common medications thought to impact PSA in a large cross-sectional study of the United States population. [...]
We all know that hormone therapy (ADT2) stops the production of testosterone and blocks the little testosterone that might still be produced from entering into the prostate cancer cell to “feed” the cancer. There have been a number of studies that have investigated and concluded that ADT not only stops testosterone, but also has anti-vascular [...]
One of the largest and most controversial issues for the treatment of advanced prostate cancer is the value of androgen-deprivation therapy (ADT). Most doctors use ADT as their pivotal initial treatment in the management of locally advanced and metastatic prostate cancer (PCa). But, the grand question is does it extend survival? […]
When Degarelix (FIRMAGON) which is a gonadotrophin-releasing hormone (GnRH) receptor blocker was first approved by the Food and Drug Administration (FDA) I contacted Ferring Pharmaceuticals and spoke with their medical director. I asked if Degarelix could be used as a second line hormone therapy drug after the traditional first line GnRH agonist drugs (Lupron etc.) [...]
(Results from the population-based PCBaSe Sweden) Hormone therapy (ADT) is designed to prevent the manufacturing of testosterone however, testosterone is a very important preventive hormone, especially in the area of heart health. ADT also causes a number of metabolic side-effects including increased body weight, insulin resistance, dyslipidemia, and hyperglycemia. So, how is the risk of [...]